Quick Answer
Vicapsys Life Sciences, Inc. reported Operating Income Loss of -$1.05 million for the year ending 2023.
- Vicapsys Life Sciences, Inc. showed a decrease of -6.3% in Operating Income Loss from 2022 to 2023.
- This data is from Vicapsys Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on October 21, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$364.5 thousand | Q2 2020: -$231.6 thousand | Q3 2020: -$89.2 thousand | Q1 2021: -$49.8 thousand | Q2 2021: -$72.1 thousand | Q3 2021: -$111.2 thousand | Q1 2022: -$167.0 thousand | Q2 2022: -$180.1 thousand | Q3 2022: -$145.1 thousand | Q1 2023: -$211.3 thousand | Q2 2023: -$135.7 thousand | Q3 2023: -$175.4 thousand | Q1 2024: -$204.3 thousand | Q2 2024: -$181.8 thousand | Q3 2024: -$198.9 thousand.
- Over the full 4 years of available data (2020 to 2023), Vicapsys Life Sciences, Inc.'s Operating Income Loss has declined by 36.7%.
- Historical annual values: Fiscal year 2023: -$1.05 million | Fiscal year 2022: -$984.8 thousand | Fiscal year 2021: -$336.9 thousand | Fiscal year 2020: -$765.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: